ATE157012T1 - Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen - Google Patents

Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen

Info

Publication number
ATE157012T1
ATE157012T1 AT90916560T AT90916560T ATE157012T1 AT E157012 T1 ATE157012 T1 AT E157012T1 AT 90916560 T AT90916560 T AT 90916560T AT 90916560 T AT90916560 T AT 90916560T AT E157012 T1 ATE157012 T1 AT E157012T1
Authority
AT
Austria
Prior art keywords
genetic material
cells
foreign genes
vivo administration
functional foreign
Prior art date
Application number
AT90916560T
Other languages
English (en)
Inventor
Kenneth L Brigham
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23712442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE157012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of ATE157012T1 publication Critical patent/ATE157012T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT90916560T 1989-11-03 1990-10-18 Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen ATE157012T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43155289A 1989-11-03 1989-11-03

Publications (1)

Publication Number Publication Date
ATE157012T1 true ATE157012T1 (de) 1997-09-15

Family

ID=23712442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90916560T ATE157012T1 (de) 1989-11-03 1990-10-18 Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen

Country Status (8)

Country Link
EP (2) EP0452457B1 (de)
JP (1) JP3056782B2 (de)
AT (1) ATE157012T1 (de)
AU (1) AU625013B2 (de)
CA (1) CA2044593C (de)
DE (1) DE69031305T2 (de)
DK (1) DK0452457T3 (de)
WO (1) WO1991006309A1 (de)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US6001644A (en) * 1991-12-17 1999-12-14 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
EP0646178A1 (de) * 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994005782A1 (en) * 1992-09-10 1994-03-17 Trustees Of Tufts College In vivo production of transgenic organ by introducing the transgene via lumen
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
ATE277175T1 (de) * 1994-07-15 2004-10-15 Merck & Co Inc Ein verfahren für die plasmidreinigung in grossem massstab
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6531455B1 (en) 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
AR003122A1 (es) * 1995-05-19 1998-07-08 Merck & Co Inc Un proceso para aislacion y purificacion de plasmidos en fermentadores de gran escala y el adn aislado y purificado obtenido mediante dicho proceso.
CA2230819C (en) 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
JP2765814B2 (ja) * 1995-11-24 1998-06-18 コナミ株式会社 ビデオゲーム装置及びビデオゲームのプレイキャラクタ成長制御方法
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
JP2002500190A (ja) 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
CA2321837C (en) 1998-02-03 2011-08-16 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
DE69940774D1 (de) 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
EP1119368A2 (de) 1999-03-03 2001-08-01 Biogen, Inc. Verfahren zür modulierung des fettstoffwechsels und lagerung
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
KR20010093804A (ko) 1999-10-08 2001-10-29 무라야마 마사노리 심근증 유전자 치료
EP1230268B1 (de) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroklitische analoga von klasse-i epitopen
EP1255822A2 (de) 1999-12-27 2002-11-13 The Regents Of The University Of California Modifizierte adenylylcyclase vom typ vi für gentheraphie bei congestiven herzkrankheiten
EP2213743A1 (de) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
EP2287186B1 (de) 2001-09-06 2014-12-31 Agensys, Inc. Nucleinsäure und entsprechendes Protein, STEAP-1, bei der Behandlung und zum Nachweis von Krebs
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
EP1565200A4 (de) 2002-11-27 2009-06-24 Agensys Inc NUKLEINSûURE ENTSPRECHENDES PROTEIN 24P4C12 ZUR BEHANDLUNG UND ERKENNUNG VON KREBS
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
JP2007524361A (ja) 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
PT1633767T (pt) 2003-06-02 2019-02-27 Univ Massachusetts Métodos e composições para controlar a eficácia do silenciamento de arn
EP1633890B2 (de) 2003-06-02 2020-11-18 University of Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
AU2004263830B2 (en) 2003-06-13 2008-12-18 Alnylam Pharmaceuticals, Inc. Double-stranded ribonucleic acid with increased effectiveness in an organism
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7608699B2 (en) 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
EP1723227A4 (de) 2004-02-10 2007-09-19 Dartmouth College Nicotinamidribosid-kinase-zusammensetzungen und verfahren zu deren verwendung
AU2005247509C1 (en) 2004-05-27 2012-09-20 Alnylam Pharmaceuticals, Inc. Nuclease resistant double-stranded ribonucleic acid
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
JP5139083B2 (ja) 2005-01-25 2013-02-06 プロレキシーズ ファーマシューティカルズ インコーポレイテッド 抗腫瘍剤としてのキノキサリン誘導体
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
WO2006133333A2 (en) 2005-06-07 2006-12-14 The Rockefeller University Stimulation of pancreatic b cell proliferation
CA2656548A1 (en) 2005-06-30 2007-01-11 Whitehead Institute Progenitor cells and uses thereof
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
JP5111385B2 (ja) 2005-10-28 2013-01-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド ハンチンチン遺伝子の発現を抑制するための組成物および方法
US20100069461A1 (en) 2005-11-09 2010-03-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2007084631A2 (en) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
PT2450437T (pt) 2006-04-14 2017-08-25 Cell Signaling Technology Inc Defeitos de genes e cinase alk mutante em tumores sólidos humanos
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
EP1920775B1 (de) 2006-10-10 2012-12-19 Gunther Prof. Dr. Hartmann 5' Triphosphat -oligonukleotid induziert eine antivirale Reaktion
EP2629094A1 (de) 2007-01-24 2013-08-21 Carnegie Mellon University Optische Biosensoren
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
JP5769968B2 (ja) 2007-10-18 2015-08-26 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
EP2612867A1 (de) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunsuppressive Polypeptide und Nucleinsäuren
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
AU2010211133A1 (en) 2009-02-03 2011-07-21 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of PTP1B genes
EP3266795A1 (de) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Verfahren zum detektieren von fig-ros-fusionspolynukleotid
US9249306B2 (en) 2009-02-18 2016-02-02 Carnegie Mellon University Quenched dendrimeric dyes for florescence detection
US9149024B2 (en) 2009-06-22 2015-10-06 Massachusetts Eye & Ear Infirmary Islet1 (Isl1) and hearing loss
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
AR078921A1 (es) 2009-11-09 2011-12-14 Hoffmann La Roche Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
EP2504439B1 (de) 2009-11-27 2016-03-02 BASF Plant Science Company GmbH Optimierte endonukleasen und ihre verwendung
CN102762726A (zh) 2009-11-27 2012-10-31 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
AU2010325563B2 (en) 2009-11-27 2017-02-02 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
US9597346B2 (en) 2010-01-15 2017-03-21 Cornell University Methods for reducing protein levels in a cell
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US20110196016A1 (en) 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
EP2569633B1 (de) 2010-05-14 2016-02-10 The General Hospital Corporation Zusammensetzungen und verfahren zur identifikation tumorspezifischer neoantigene
WO2011150079A1 (en) 2010-05-25 2011-12-01 Carnegie Mellon University Targeted probes of cellular physiology
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP3434772A3 (de) 2010-10-18 2019-03-20 Arrowhead Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
EP2659271A4 (de) 2010-12-27 2015-04-08 Univ Brown Therapeutische und diagnostische verfahren mit biglycan und utrophin
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
EA024762B9 (ru) 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
EP2760463B1 (de) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulierung der natriumkanäle durch plunc-proteine
RU2014118727A (ru) 2011-10-11 2015-11-20 Новартис Аг Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
EP2785370B1 (de) 2011-12-02 2021-07-21 Rhode Island Hospital Impfstoff gegen falciparum-malaria
EP2612918A1 (de) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta-Rekombination
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
CA2908253C (en) 2013-04-04 2024-01-09 Trustees Of Dartmouth College Compositions and methods for in vivo excision of hiv-1 proviral dna
EP2983702A2 (de) 2013-04-07 2016-02-17 The Broad Institute, Inc. Zusammensetzungen und verfahren für personalisierte neoplasieimpfstoffe
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
HK1221912A1 (zh) 2013-10-04 2017-06-16 Novartis Ag 用於治疗乙肝病毒的有机化合物
EP3052464B1 (de) 2013-10-04 2020-04-15 Novartis AG 3 endkappen für rnai-mittel zur verwendung in der rna-interferenz
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
CN106459993A (zh) 2014-03-31 2017-02-22 德彪药业国际股份公司 Fgfr融合体
US12359197B2 (en) 2014-12-12 2025-07-15 Etagen Pharma, Inc. Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3748007B1 (de) 2015-03-06 2024-06-26 Massachusetts Eye & Ear Infirmary Genaugmentationstherapien für hereditäre netzhautdegeneration durch mutationen im prpf31-gen
WO2016183585A1 (en) 2015-05-14 2016-11-17 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
WO2017127473A1 (en) 2016-01-19 2017-07-27 The University Of North Carolina At Chapel Hill Methods and compositions using rna interference for inhibition of kras
US10894811B2 (en) 2016-02-22 2021-01-19 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
JP2019513373A (ja) 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CA3022319A1 (en) 2016-05-06 2017-11-09 Tod M. Woolf Improved methods for genome editing with and without programmable nucleases
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
US11795201B2 (en) 2017-04-14 2023-10-24 University Of Massachusetts Brown fat-selective adipokines
EP3634449A4 (de) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. Alphavirus-neoantigen-vektoren
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
AU2018279627B2 (en) 2017-06-09 2023-08-10 Seattle Project Corp. Neoantigen identification, manufacture, and use
EP4576103A3 (de) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigenidentifizierung mit hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
US12582702B2 (en) 2018-05-11 2026-03-24 University Of Massachusetts Methods for improving leptin sensitivity for the treatment of obesity and diabetes
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
KR20220042116A (ko) 2019-06-18 2022-04-04 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
CA3143679A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
JP7711045B2 (ja) 2019-09-02 2025-07-22 アンスティテュ・クリー 腫瘍ネオアンチゲンペプチドを標的とする免疫療法
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
CN115427568A (zh) 2020-02-12 2022-12-02 麻省眼耳科医院 Rp1相关视网膜变性的基于单倍型的治疗
US20230212243A1 (en) 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
EP4229204A1 (de) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Nukleinsäurekonstrukte zur gleichzeitigen genaktivierung
CA3197730A1 (en) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Nucleic acid constructs for va rna transcription
JP2024501482A (ja) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
EP4277933A4 (de) 2021-01-14 2024-12-11 Senti Biosciences, Inc. Sekretierbare nutzlastregulierung
KR20240006721A (ko) 2021-03-11 2024-01-15 엥스띠뛰 퀴리 막 형질 전환 네오 안티젠 펩타이드
AU2022233019A1 (en) 2021-03-11 2023-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Tumor neoantigenic peptides
US20240182523A1 (en) 2021-03-22 2024-06-06 The University Of North Carolina At Chapel Hill Modified peptidomimetics and methods of use
US20250302930A1 (en) 2022-03-24 2025-10-02 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
CN119563028A (zh) 2022-05-12 2025-03-04 尚威天成信使核糖核酸治疗公司 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
JP2025522297A (ja) 2022-05-25 2025-07-15 ビオンテック エスエー サルポックス抗原の送達のためのｒｎａ組成物及び関連する方法
CN114958912B (zh) * 2022-05-30 2023-11-10 新乡医学院 一种hek293细胞瞬时表达转染用试剂和瞬时表达系统转染方法
WO2025030097A2 (en) 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025088117A1 (en) 2023-10-25 2025-05-01 Rheinische Friedrich-Wilhelms-Universität Bonn Ribonucleic acid construct capable of inducing an immune response, as well as pharmaceutical composition and kit comprising same
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025158069A1 (en) 2024-01-25 2025-07-31 Rheinische Friedrich-Wilhelms-Universität Bonn CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025189168A1 (en) 2024-03-08 2025-09-12 SunVax mRNA Therapeutics Inc. Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026047025A1 (en) 2024-08-27 2026-03-05 Rheinische Friedrich-Wilhelms-Universität Bonn Photocontrollable conjugate, pharmaceutical composition and kit comprising the same, and uses thereof
EP4702988A1 (de) 2024-08-28 2026-03-04 Biotechnology Assets S.A. Kombinationsprodukt zur behandlung von leishmaniose
WO2026062222A1 (en) 2024-09-20 2026-03-26 Institut Curie Novel protein isoforms and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2942780A1 (de) * 1979-10-23 1981-05-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
NZ219392A (en) * 1986-02-28 1989-05-29 Smithkline Beckman Corp Production of an immortalised primary cell line
EP0386185A1 (de) * 1988-07-29 1990-09-12 IntraCel Corporation Verfahren zur genexpression von heterologischen proteinen durch in-vivo-zelltransfektion
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates

Also Published As

Publication number Publication date
WO1991006309A1 (en) 1991-05-16
DK0452457T3 (da) 1998-03-02
EP0452457B1 (de) 1997-08-20
CA2044593A1 (en) 1991-05-04
DE69031305T2 (de) 1998-03-26
CA2044593C (en) 2004-04-20
EP0452457A4 (en) 1993-02-17
AU6645690A (en) 1991-05-31
JP3056782B2 (ja) 2000-06-26
EP0800830A3 (de) 1999-03-17
AU625013B2 (en) 1992-06-25
JPH04502772A (ja) 1992-05-21
EP0800830A2 (de) 1997-10-15
DE69031305D1 (de) 1997-09-25
EP0452457A1 (de) 1991-10-23

Similar Documents

Publication Publication Date Title
ATE157012T1 (de) Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
ATE195551T1 (de) System und verfahren zur transplantation von zellen
DE3856505D1 (de) Proteine mit Faktor VIII Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende Zusammensetzungen
DE69426328D1 (de) Verwendung von mesothelialen zellen in der gentherapie
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
ATE172493T1 (de) Rekombinante dns-mittel und verfahren
DE69533223D1 (de) Zusammensetzungen und verfahren zur stimulierung der proliferation und der differenzierung von menschlichen fetalen und erwachsenen pankreatischen zellen ex vivo
EP0279582A3 (de) DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
IL68366A (en) Process for expressing a gene encoding a protein comprising the enzymatic portion of human urokinase in a microorganism or cell culture
ATE211166T1 (de) Zellkulturmatrix und biologisch abbaubare dreidimensionale matrix auf hyaluronsäurederivatbasis
ATE69241T1 (de) Herstellung von polypeptiden mit humangammainterferon-aktivitaet.
NO890833L (no) Fremstilling av kallikrein.
ATE243741T1 (de) Zufuhr von genprodukten mittels mesangium-zellen
DE69833264D1 (de) Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen
DE68929370D1 (de) Verfahren zur Selektion und zur stabilen Einschleusung rekombinanter DNA in Milchsäurebakterien
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
ATE82319T1 (de) Verfahren zur herstellung von aktivierten toetenden zellen.
Taichman et al. Maturation of human gingival keratinocytes cultured with fibroblasts from keratinizing and non-keratinizing epithelia
ES2058274T3 (es) Un metodo para expresar un producto genico heterologo no bacteriano.
IL83622A0 (en) In vivo administration of genetic material to animals
ITRM940345A0 (it) "metodo per la amplificazione in vitro e l'espressione in cellule di mammifero di sequenza esogene di acidi nucleici"
IL79913A0 (en) In vivo administration of genetic material to animals
ATE59204T1 (de) Verfahren zum einbringen von klonierten amplifizierbaren genen in eukaryotische zellen und zur herstellung von proteinprodukten.
TH9321A (th) ผลิตภัณฑ์ปรากฎการณ์ใหม่สำหรับการรักษามะเร็ง
PT88807A (pt) Processo para a amplificacao de genes e para a preparacao melhorada de proteinas em culturas de celulas animais

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked